Cardiovascular Effects of Combining Subcutaneous or Intravenous Esketamine and the MAO Inhibitor Tranylcypromine for the Treatment of Depression: A Retrospective Cohort Study.

CNS Drugs · 2021 · PMC8354966 · PMID 34283390

Europe PMC DOI

hedged sentence

0.0060

closest p · 0.1× alpha

0.0060

boldest claim

The sentences

failed to reach statistical significancep = 0.006actually significant

Sensitivity analysis revealed no differences, and only mean absolute DBP failed to reach statistical significance ( F [1,371] = 7.50, p = 0.006), unlike in the full sample.

also in 6,035 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.